Dapivirine is an experimental non-nucleoside reverse transcriptase inhibitor. A gel formulation of dapivirine is now being investigated as a vaginal microbicide.
In an open-label study of women in southern and eastern Africa, a vaginal ring that is inserted once a month and slowly releases an antiviral drug was estimated to reduce the risk of HIV by 39%, according to statistical modeling.
A clinical trial has begun to examine the safety and use of two HIV prevention tools--oral pre-exposure prophylaxis and a vaginal ring--in adolescent girls and young women in southern Africa.
AIDS is already the leading cause of death among girls and young women in much of Africa, and matters could only get worse, given that for every day that passes, 1,000 more girls ages 15 to 24 are likely to become infected with HIV.
The nonprofit International Partnership for Microbicides announced today the start of the first clinical trial of vaginal rings designed to slowly release the antiretroviral drug dapivirine over three months to prevent HIV in women.
The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults.
Most women who used an experimental vaginal ring for HIV prevention report that the physical act of sex was largely unaffected by using the product, which is inserted monthly for continuous wear.
Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part of a new study called HOPE.
In an important scientific achievement for women's health, two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug (ARV) dapivirine can safely help prevent HIV-1 infection in women.
In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing HIV in women.
ASPIRE, one of two Phase III trials of a promising method for preventing HIV in women - a vaginal ring worn for a month at a time - has completed enrollment of participants, with 2,629 women from 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe now taking part in the study.
The International Partnership for Microbicides announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.
Findings of an early phase clinical trial at the University of Alabama at Birmingham suggest that a possible new method of protecting women from the transmission of HIV is safe.
Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.
Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.
The International Partnership for Microbicides (IPM) announced today that it has received two competitive five-year awards with a combined US$40 million ceiling from the US Agency for International Development (USAID).
A large clinical trial testing the long-term safety and effectiveness of a new approach for preventing HIV in women - a vaginal ring used once a month - is now underway in Africa, researchers announced today at the XIX International AIDS Conference (AIDS 2012).
GlobalPost's "Global Pulse" blog features an interview with Zeda Rosenberg, CEO of the International Partnership for Microbicides (IPM), in which she discusses a study of a vaginal ring containing the antiretroviral (ARV) dapivirine.
"This week, at the Pacific Health Summit in London, the final large-scale trial was officially launched of a vaginal ring which women can wear and forget about -- at least for a month at a time -- while it releases an HIV virus-killing drug called dapivirine," the Guardian reports.
An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today.